Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
NEW ORLEANS, May 04, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (Nasdaq:MYGN), if they purchased the Company’s securities between August 13, 2014 through March 12, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Utah.
Get Help
Myriad investors should visit us at https://www.claimsfiler.com/cases/view-myriad-genetics-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Myriad Genetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services, regarding “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid,” specifically relating to the Company’s hereditary cancer testing dating back to January 1, 2014 (less than four months after the Company launched its myRisk test in September 2013) to the date of the subpoena’s issuance.
On this news, the price of Myriad’s shares plummeted over 12.14%
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
